Transaction · 0001104659-26-011616

Myers Michael

Myers Michael, CEO, reported a transaction classified as grant at Quoin Pharmaceuticals, Ltd. involving 318750.000000 shares for an estimated $0.00. Reported holdings after the transaction were 318750.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO
QNRXQuoin Pharmaceuticals, Ltd.
Filing timeFeb 06
Trade dateFeb 04, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$7.14
Pre-filing
1mo ago +96.8%1w ago +27.5%1d ago +5.5%
Returns since
7d +17.6%30d +21.4%90d -10.8%180d -38.8%1y -24.6%

QNRX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
QNRX since 2026-02-06Filed 209 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001104659-26-011616
Share Option (Right to Buy)
Transaction date
Feb 04, 2026
Filed Feb 06, 2026, 10:18 PM · 2d delay
Shares
318k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
318k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Increase
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

  2. F2

    The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

Original filing · 0001104659-26-011616
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

QNRX